Nascent Biotech, Inc. (NBIO)
OTCMKTS: NBIO · Delayed Price · USD
0.0999
+0.0146 (17.16%)
Apr 24, 2024, 11:03 AM EDT - Market open
Company Description
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer.
It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation.
In addition, it develops CLNH5. The company has collaboration with Hypospray Pharma to develop an alternative delivery mechanism for patients who can benefit from Pritumumab.
Nascent Biotech, Inc. is based in North Palm Beach, Florida.
Nascent Biotech, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Sean Carrick |
Contact Details
Address: 631 Us Hwy 1, Suite 407 North Palm Beach, Florida 33408 United States | |
| Phone | 612-961-5656 |
| Website | nascentbiotech.com |
Stock Details
| Ticker Symbol | NBIO |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001622057 |
| CUSIP Number | 63108Q101 |
| ISIN Number | US63108Q1013 |
| Employer ID | 45-0612715 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sean Carrick | President, Chief Executive Officer, Secretary and Director |
| Lowell Holden | Chief Financial Officer, Chief Accounting Officer and Director |
| Dr. Mark C. Glassy Ph.D. | Founder |
| Dr. Navpaul Singh M.D. | Chief Medical Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2024 | EFFECT | Notice of Effectiveness |
| Apr 3, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 29, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 15, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Feb 14, 2024 | 10-Q | Quarterly Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 19, 2023 | 8-K | Current Report |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Sep 6, 2023 | 8-K | Current Report |
| Aug 18, 2023 | 10-Q | Quarterly Report |